Connect
MJA
MJA

Re-treating bleeding hereditary haemorrhagic telangiectasia with bevacizumab

Gwo Yaw Ho, Edward Zhong and Boris Chern
Med J Aust 2013; 199 (10): 658. || doi: 10.5694/mja13.10260
Published online: 18 November 2013

To the Editor: Symptomatic bleeding in patients with hereditary haemorrhagic telangiectasia (HHT) has been reported to respond to bevacizumab treatment. In this Journal in March 2011, Cruikshank and Chern described the successful treatment of gastric HHT with bevacizumab.1 Here, we present the result of a rechallenge with bevacizumab in the same patient.

  • Gwo Yaw Ho1
  • Edward Zhong2
  • Boris Chern1

  • 1 Oncology Department, Redcliffe Hospital, Brisbane, QLD.
  • 2 University of Queensland, Brisbane, QLD.

Correspondence: hogwoyaw@doctors.org.uk

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.